{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T18:22:16Z","timestamp":1788805336577,"version":"build-2803163510"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Allergan\/AbbVie"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s40265-025-02157-1","type":"journal-article","created":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T09:58:45Z","timestamp":1739440725000},"page":"397-414","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Prospective 18-Month Study of Bimatoprost Intracameral Implant in Patients with Open-Angle Glaucoma or Ocular Hypertension in US Clinical Practice"],"prefix":"10.1007","volume":"85","clinical-trial-number":[{"clinical-trial-number":"nct04647214","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Eric","family":"Mann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9422-4771","authenticated-orcid":false,"given":"Jeffrey A.","family":"Kammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gagan","family":"Sawhney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7811-8357","authenticated-orcid":false,"given":"Jella","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica C.","family":"Werts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Vera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos","family":"Rivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxin","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadhana","family":"Sonparote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2077-659X","authenticated-orcid":false,"given":"E. Randy","family":"Craven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,13]]},"reference":[{"key":"2157_CR1","doi-asserted-by":"publisher","first-page":"13762","DOI":"10.1038\/s41598-021-92971-w","volume":"11","author":"N Zhang","year":"2021","unstructured":"Zhang N, Wang J, Li Y, Jiang B. Prevalence of primary open angle glaucoma in the last 20 years: a meta-analysis and systematic review. Sci Rep. 2021;11:13762. https:\/\/doi.org\/10.1038\/s41598-021-92971-w.","journal-title":"Sci Rep"},{"key":"2157_CR2","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1016\/j.ophtha.2014.05.013","volume":"121","author":"YC Tham","year":"2014","unstructured":"Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121:2081\u201390. https:\/\/doi.org\/10.1016\/j.ophtha.2014.05.013.","journal-title":"Ophthalmology"},{"key":"2157_CR3","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1001\/archopht.121.1.48","volume":"121","author":"MC Leske","year":"2003","unstructured":"Leske MC, Heijl A, Hussein M, Bengtsson B, Hyman L, Komaroff E. Factors for glaucoma progression and the effect of treatment: the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2003;121:48\u201356. https:\/\/doi.org\/10.1001\/archopht.121.1.48.","journal-title":"Arch Ophthalmol"},{"key":"2157_CR4","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/s0140-6736(14)62111-5","volume":"385","author":"DF Garway-Heath","year":"2015","unstructured":"Garway-Heath DF, Crabb DP, Bunce C, Lascaratos G, Amalfitano F, Anand N, et al. Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial. Lancet. 2015;385:1295\u2013304. https:\/\/doi.org\/10.1016\/s0140-6736(14)62111-5.","journal-title":"Lancet"},{"key":"2157_CR5","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1001\/archopht.120.6.701","volume":"120","author":"MA Kass","year":"2002","unstructured":"Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701\u201313. https:\/\/doi.org\/10.1001\/archopht.120.6.701. (discussion 829\u201330).","journal-title":"Arch Ophthalmol"},{"key":"2157_CR6","doi-asserted-by":"publisher","first-page":"P71","DOI":"10.1016\/j.ophtha.2020.10.022","volume":"128","author":"SJ Gedde","year":"2021","unstructured":"Gedde SJ, Vinod K, Wright MM, Muir KW, Lind JT, Chen PP, et al. Primary open-angle glaucoma Preferred Practice Pattern\u00ae. Ophthalmology. 2021;128:P71-150.","journal-title":"Ophthalmology"},{"key":"2157_CR7","doi-asserted-by":"publisher","first-page":"P151","DOI":"10.1016\/j.ophtha.2020.10.023","volume":"128","author":"SJ Gedde","year":"2021","unstructured":"Gedde SJ, Lind JT, Wright MM, Chen PP, Muir KW, Vinod K, et al. Primary open-angle glaucoma suspect Preferred Practice Pattern\u00ae. Ophthalmology. 2021;128:P151\u201392. https:\/\/doi.org\/10.1016\/j.ophtha.2020.10.023.","journal-title":"Ophthalmology"},{"key":"2157_CR8","doi-asserted-by":"publisher","first-page":"539","DOI":"10.2147\/jep.S281187","volume":"12","author":"V Jayanetti","year":"2020","unstructured":"Jayanetti V, Sandhu S, Lusthaus JA. The latest drugs in development that reduce intraocular pressure in ocular hypertension and glaucoma. J Exp Pharmacol. 2020;12:539\u201348. https:\/\/doi.org\/10.2147\/jep.S281187.","journal-title":"J Exp Pharmacol"},{"key":"2157_CR9","doi-asserted-by":"publisher","first-page":"441","DOI":"10.2147\/ppa.S23780","volume":"5","author":"G Reardon","year":"2011","unstructured":"Reardon G, Kotak S, Schwartz GF. Objective assessment of compliance and persistence among patients treated for glaucoma and ocular hypertension: a systematic review. Patient Prefer Adherence. 2011;5:441\u201363. https:\/\/doi.org\/10.2147\/ppa.S23780.","journal-title":"Patient Prefer Adherence"},{"key":"2157_CR10","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1080\/17469899.2019.1635456","volume":"14","author":"AL Robin","year":"2019","unstructured":"Robin AL, Muir KW. Medication adherence in patients with ocular hypertension or glaucoma. Expert Rev Ophthalmol. 2019;14:199\u2013210. https:\/\/doi.org\/10.1080\/17469899.2019.1635456.","journal-title":"Expert Rev Ophthalmol."},{"key":"2157_CR11","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.ophtha.2004.12.035","volume":"112","author":"CM Olthoff","year":"2005","unstructured":"Olthoff CM, Schouten JS, van de Borne BW, Webers CA. Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension an evidence-based review. Ophthalmology. 2005;112:953\u201361. https:\/\/doi.org\/10.1016\/j.ophtha.2004.12.035.","journal-title":"Ophthalmology"},{"issue":"Suppl. 1","key":"2157_CR12","doi-asserted-by":"publisher","first-page":"S57","DOI":"10.1016\/j.survophthal.2008.08.002","volume":"53","author":"GF Schwartz","year":"2008","unstructured":"Schwartz GF, Quigley HA. Adherence and persistence with glaucoma therapy. Surv Ophthalmol. 2008;53(Suppl. 1):S57-68. https:\/\/doi.org\/10.1016\/j.survophthal.2008.08.002.","journal-title":"Surv Ophthalmol"},{"key":"2157_CR13","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1016\/j.ophtha.2015.06.039","volume":"122","author":"PA Newman-Casey","year":"2015","unstructured":"Newman-Casey PA, Blachley T, Lee PP, Heisler M, Farris KB, Stein JD. Patterns of glaucoma medication adherence over four years of follow-up. Ophthalmology. 2015;122:2010\u201321. https:\/\/doi.org\/10.1016\/j.ophtha.2015.06.039.","journal-title":"Ophthalmology"},{"key":"2157_CR14","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.ophtha.2019.10.022","volume":"127","author":"PA Newman-Casey","year":"2020","unstructured":"Newman-Casey PA, Niziol LM, Gillespie BW, Janz NK, Lichter PR, Musch DC. The association between medication adherence and visual field progression in the Collaborative Initial Glaucoma Treatment Study. Ophthalmology. 2020;127:477\u201383. https:\/\/doi.org\/10.1016\/j.ophtha.2019.10.022.","journal-title":"Ophthalmology"},{"key":"2157_CR15","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1097\/ijg.0000000000001943","volume":"30","author":"YH Shu","year":"2021","unstructured":"Shu YH, Wu J, Luong T, Mattox C, Fang EN, Lee BL, et al. Topical medication adherence and visual field progression in open-angle glaucoma: analysis of a large US health care system. J Glaucoma. 2021;30:1047\u201355. https:\/\/doi.org\/10.1097\/ijg.0000000000001943.","journal-title":"J Glaucoma"},{"key":"2157_CR16","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1016\/j.ophtha.2010.03.040","volume":"117","author":"AL Hennessy","year":"2010","unstructured":"Hennessy AL, Katz J, Covert D, Protzko C, Robin AL. Videotaped evaluation of eyedrop instillation in glaucoma patients with visual impairment or moderate to severe visual field loss. Ophthalmology. 2010;117:2345\u201352. https:\/\/doi.org\/10.1016\/j.ophtha.2010.03.040.","journal-title":"Ophthalmology"},{"key":"2157_CR17","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1097\/opx.0000000000000009","volume":"90","author":"LE Dreer","year":"2013","unstructured":"Dreer LE, Girkin CA, Campbell L, Wood A, Gao L, Owsley C. Glaucoma medication adherence among African Americans: program development. Optom Vis Sci. 2013;90:883\u201397. https:\/\/doi.org\/10.1097\/opx.0000000000000009.","journal-title":"Optom Vis Sci"},{"key":"2157_CR18","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1016\/j.ophtha.2015.03.026","volume":"122","author":"PA Newman-Casey","year":"2015","unstructured":"Newman-Casey PA, Robin AL, Blachley T, Farris K, Heisler M, Resnicow K, et al. The most common barriers to glaucoma medication adherence: a cross-sectional survey. Ophthalmology. 2015;122:1308\u201316. https:\/\/doi.org\/10.1016\/j.ophtha.2015.03.026.","journal-title":"Ophthalmology"},{"key":"2157_CR19","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/ijpp.12215","volume":"24","author":"R Sayner","year":"2016","unstructured":"Sayner R, Carpenter DM, Robin AL, Blalock SJ, Muir KW, Vitko M, et al. How glaucoma patient characteristics, self-efficacy and patient-provider communication are associated with eye drop technique. Int J Pharm Pract. 2016;24:78\u201385. https:\/\/doi.org\/10.1111\/ijpp.12215.","journal-title":"Int J Pharm Pract"},{"key":"2157_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0251699","volume":"16","author":"K Kashiwagi","year":"2021","unstructured":"Kashiwagi K, Matsuda Y, Ito Y, Kawate H, Sakamoto M, Obi S, et al. Investigation of visual and physical factors associated with inadequate instillation of eyedrops among patients with glaucoma. PLoS ONE. 2021;16: e0251699. https:\/\/doi.org\/10.1371\/journal.pone.0251699.","journal-title":"PLoS ONE"},{"key":"2157_CR21","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1097\/ijg.0000000000001965","volume":"31","author":"J Gatwood","year":"2022","unstructured":"Gatwood J, Brooks C, Meacham R, Abou-Rahma J, Cernasev A, Brown E, et al. Facilitators and barriers to glaucoma medication adherence. J Glaucoma. 2022;31:31\u20136. https:\/\/doi.org\/10.1097\/ijg.0000000000001965.","journal-title":"J Glaucoma"},{"key":"2157_CR22","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1007\/s40123-023-00797-8","volume":"12","author":"SG Moore","year":"2023","unstructured":"Moore SG, Richter G, Modjtahedi BS. Factors affecting glaucoma medication adherence and interventions to improve adherence: a narrative review. Ophthalmol Ther. 2023;12:2863\u201380. https:\/\/doi.org\/10.1007\/s40123-023-00797-8.","journal-title":"Ophthalmol Ther"},{"key":"2157_CR23","unstructured":"Newman-Casey PA, Rhee DJ, Robin AL, Mansberger SL. Patient challenges with glaucoma eye drops: a need to identify nonadherence and facilitate appropriate support and disease management. Ophthalmol Glaucoma. (in press)."},{"key":"2157_CR24","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1007\/s40123-023-00730-z","volume":"12","author":"L Quaranta","year":"2023","unstructured":"Quaranta L, Novella A, Tettamanti M, Pasina L, Weinreb RN, Nobili A. Adherence and persistence to medical therapy in glaucoma: an overview. Ophthalmol Ther. 2023;12:2227\u201340. https:\/\/doi.org\/10.1007\/s40123-023-00730-z.","journal-title":"Ophthalmol Ther"},{"key":"2157_CR25","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1080\/03007995.2024.2322048","volume":"40","author":"MF Cordeiro","year":"2024","unstructured":"Cordeiro MF, Denis P, Astarita C, Belsey J, Rivas M, Garc\u00eda-Feijoo J. Prevalence of comorbidities with the potential to increase the risk of nonadherence to topical ocular hypotensive medication in patients with open-angle glaucoma. Curr Med Res Opin. 2024;40:647\u201355. https:\/\/doi.org\/10.1080\/03007995.2024.2322048.","journal-title":"Curr Med Res Opin"},{"key":"2157_CR26","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.ajo.2016.11.020","volume":"175","author":"RA Lewis","year":"2017","unstructured":"Lewis RA, Christie WC, Day DG, Craven ER, Walters T, Bejanian M, et al. Bimatoprost sustained-release implants for glaucoma therapy: 6-month results from a phase I\/II clinical trial. Am J Ophthalmol. 2017;175:137\u201347. https:\/\/doi.org\/10.1016\/j.ajo.2016.11.020.","journal-title":"Am J Ophthalmol"},{"key":"2157_CR27","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1016\/j.ophtha.2020.06.018","volume":"127","author":"FA Medeiros","year":"2020","unstructured":"Medeiros FA, Walters TR, Kolko M, Coote M, Bejanian M, Goodkin ML, et al. Phase 3, randomized, 20-month study of bimatoprost implant in open-angle glaucoma and ocular hypertension (ARTEMIS 1). Ophthalmology. 2020;127:1627\u201341. https:\/\/doi.org\/10.1016\/j.ophtha.2020.06.018.","journal-title":"Ophthalmology"},{"key":"2157_CR28","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1089\/jop.2022.0137","volume":"39","author":"RN Weinreb","year":"2023","unstructured":"Weinreb RN, Bacharach J, Brubaker JW, Medeiros FA, Bejanian M, Bernstein P, et al. Bimatoprost implant biodegradation in the phase 3, randomized, 20-month ARTEMIS studies. J Ocul Pharmacol Ther. 2023;39:55\u201362. https:\/\/doi.org\/10.1089\/jop.2022.0137.","journal-title":"J Ocul Pharmacol Ther"},{"key":"2157_CR29","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1007\/s40265-021-01624-9","volume":"81","author":"J Bacharach","year":"2021","unstructured":"Bacharach J, Tatham A, Ferguson G, Belalc\u00e1zar S, Thieme H, Goodkin ML, et al. Phase 3, randomized, 20-month study of the efficacy and safety of bimatoprost implant in patients with open-angle glaucoma and ocular hypertension (ARTEMIS 2). Drugs. 2021;81:2017\u201333. https:\/\/doi.org\/10.1007\/s40265-021-01624-9.","journal-title":"Drugs"},{"key":"2157_CR30","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s40265-019-01248-0","volume":"80","author":"ER Craven","year":"2020","unstructured":"Craven ER, Walters T, Christie WC, Day DG, Lewis RA, Goodkin ML, et al. 24-Month phase I\/II clinical trial of bimatoprost sustained-release implant (bimatoprost SR) in glaucoma patients. Drugs. 2020;80:167\u201379. https:\/\/doi.org\/10.1007\/s40265-019-01248-0.","journal-title":"Drugs"},{"key":"2157_CR31","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1007\/s40123-022-00527-6","volume":"11","author":"FA Medeiros","year":"2022","unstructured":"Medeiros FA, Sheybani A, Shah MM, Rivas M, Bai Z, Werts E, et al. Single administration of intracameral bimatoprost implant 10 \u00b5g in patients with open-angle glaucoma or ocular hypertension. Ophthalmol Ther. 2022;11:1517\u201337. https:\/\/doi.org\/10.1007\/s40123-022-00527-6.","journal-title":"Ophthalmol Ther"},{"key":"2157_CR32","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.ogla.2023.06.007","volume":"6","author":"RN Weinreb","year":"2023","unstructured":"Weinreb RN, Christie WC, Medeiros FA, Craven ER, Kim K, Nguyen A, et al. Single administration of bimatoprost implant: effects on 24-hour intraocular pressure and 1-year outcomes. Ophthalmol Glaucoma. 2023;6:599\u2013608. https:\/\/doi.org\/10.1016\/j.ogla.2023.06.007.","journal-title":"Ophthalmol Glaucoma."},{"key":"2157_CR33","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1089\/jop.2023.0013","volume":"39","author":"W Xu","year":"2023","unstructured":"Xu W, Zhou P, Kansara ND, Frankfort BJ, Blieden LS, Chang PT. Intraocular pressure and eyedrop usage reduction with intracameral bimatoprost implant. J Ocul Pharmacol Ther. 2023;39:398\u2013403. https:\/\/doi.org\/10.1089\/jop.2023.0013.","journal-title":"J Ocul Pharmacol Ther"},{"key":"2157_CR34","doi-asserted-by":"publisher","first-page":"187","DOI":"10.2147\/opth.S445005","volume":"18","author":"S Teymoorian","year":"2024","unstructured":"Teymoorian S, Craven ER, Nguyen L, Werts E. Real-world study of the effectiveness and safety of intracameral bimatoprost implant in a clinical setting in the United States. Clin Ophthalmol. 2024;18:187\u201399. https:\/\/doi.org\/10.2147\/opth.S445005.","journal-title":"Clin Ophthalmol"},{"key":"2157_CR35","doi-asserted-by":"publisher","first-page":"917","DOI":"10.2147\/opth.S452159","volume":"18","author":"SR Sarkisian Jr","year":"2024","unstructured":"Sarkisian SR Jr, Mitchell EC. Real-world analysis of the efficacy of bimatoprost sustained-release glaucoma implant where American Indians comprise the largest minority population. Clin Ophthalmol. 2024;18:917\u201327. https:\/\/doi.org\/10.2147\/opth.S452159.","journal-title":"Clin Ophthalmol"},{"key":"2157_CR36","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.2147\/opth.S450220","volume":"18","author":"AA Ali","year":"2024","unstructured":"Ali AA, Avil\u00e9s Elescano D, Grover DS. Bimatoprost SR for glaucoma therapy implanted at the slit-lamp in a real-world setting. Clin Ophthalmol. 2024;18:1371\u20137. https:\/\/doi.org\/10.2147\/opth.S450220.","journal-title":"Clin Ophthalmol"},{"key":"2157_CR37","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1097\/00061198-200304000-00009","volume":"12","author":"P Nelson","year":"2003","unstructured":"Nelson P, Aspinall P, Papasouliotis O, Worton B, O\u2019Brien C. Quality of life in glaucoma and its relationship with visual function. J Glaucoma. 2003;12:139\u201350. https:\/\/doi.org\/10.1097\/00061198-200304000-00009.","journal-title":"J Glaucoma"},{"key":"2157_CR38","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1007\/s40265-024-02074-9","volume":"84","author":"IP Singh","year":"2024","unstructured":"Singh IP, Berdahl JP, Sarkisian SR Jr, Voskanyan LA, Ang RE, Doan LV, et al. Long-term safety and efficacy evaluation of travoprost intracameral implant based on pooled analyses from two phase III trials. Drugs. 2024;84:1299\u2013311. https:\/\/doi.org\/10.1007\/s40265-024-02074-9.","journal-title":"Drugs"},{"key":"2157_CR39","first-page":"779","volume":"38","author":"WM Bourne","year":"1997","unstructured":"Bourne WM, Nelson LR, Hodge DO. Central corneal endothelial cell changes over a ten-year period. Invest Ophthalmol Vis Sci. 1997;38:779\u201382.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2157_CR40","doi-asserted-by":"publisher","unstructured":"Kolko M, Tatham AJ, Lim KS, Wells AP, Shiu M, Uy HS, et al. Phase 3, randomized, comparison study of intracameral bimatoprost implant 10 \u00b5g and selective laser trabeculoplasty. Am J Ophthalmol. 2025;272:19\u201337. https:\/\/doi.org\/10.1016\/j.ajo.2024.12.026.","DOI":"10.1016\/j.ajo.2024.12.026"},{"key":"2157_CR41","doi-asserted-by":"publisher","unstructured":"KWu JH, Varkhedi V, Radha Saseendrakumar B, Acuff K, Weinreb RN, Baxter SL. Social and healthcare utilization factors associated with ophthalmic visit non-adherence in glaucoma: an All of Us study. J Glaucoma. 2023. https:\/\/doi.org\/10.1097\/ijg.0000000000002300","DOI":"10.1097\/ijg.0000000000002300"},{"key":"2157_CR42","doi-asserted-by":"publisher","unstructured":"Leiby BE, Hegarty SE, Zhan T, Myers JS, Katz LJ, Haller JA, et al. A randomized trial to improve adherence to follow-up eye examinations among people with glaucoma. Preventing Chronic Disease. 2021;18:E52. https:\/\/doi.org\/10.5888\/pcd18.200567.","DOI":"10.5888\/pcd18.200567"},{"key":"2157_CR43","doi-asserted-by":"publisher","unstructured":"Ianchulev T, Weinreb RN, Calvo EA, Lewis J, Kamthan G, Sheybani A, et al. Bio-interventional cyclodialysis and allograft scleral reinforcement for uveoscleral outflow enhancement in open-angle glaucoma patients: one-year clinical outcomes. Clin Ophthalmol. 2024;18:3605\u201314. https:\/\/doi.org\/10.2147\/opth.S496631.","DOI":"10.2147\/opth.S496631"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02157-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-025-02157-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02157-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T09:34:07Z","timestamp":1741599247000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-025-02157-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,13]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["2157"],"URL":"https:\/\/doi.org\/10.1007\/s40265-025-02157-1","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,13]]},"assertion":[{"value":"6 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Allergan (prior to its acquisition by AbbVie) and\/or AbbVie funded this study and participated in the study design, research, analysis, data collection, interpretation of data, reviewing, and approval of the publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Eric Mann and Gagan Sawhney are speakers for AbbVie. Jeffrey A. Kammer has no disclosures. Jella An has previously served as a consultant for AbbVie. Erica C. Werts, Vanessa Vera, Marcos Rivas, Hongxin Lai, Sadhana Sonparote, and E. Randy Craven are employees of AbbVie and may hold AbbVie stock.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"Institutional review board or independent ethics committee approval was obtained at each site before the study began, and the study was performed in compliance with Good Clinical Practice, the principles of the Declaration of Helsinki, and applicable laws and regulations (ClinicalTrials.gov registration number NCT04647214).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All patients in this study provided written informed consent before undergoing any study-related procedure.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual, and trial-level data (analysis data sets), as well as other information (e.g., protocols, clinical study reports, or analysis plans), provided the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.These clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal, statistical analysis plan, and execution of a data sharing agreement. Data requests can be submitted at any time after approval in the USA and Europe and after acceptance of this manuscript for publication. The data will be accessible for 12 months, with possible extensions considered. For more information on the process or to submit a request, visit the following link:\n                      \n                      .","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Study design: ECW, VV, MR, ERC; data collection: EM, JAK, GS, JA; statistical analysis: HL; data interpretation: EM, JAK, GS, JA, ECW, VV, MR, HL, SS, ERC; drafting, revisions, and approval of the manuscript: EM, JAK, GS, JA, ECW, VV, MR, HL, SS, ERC.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}